Literature DB >> 7180912

Osteomalacia in chronic renal failure: a syndrome previously reported only with maintenance dialysis.

A J Felsenfeld, R A Gutman, F Llach, J M Harrelson.   

Abstract

Osteomalacia without marked elevations of parathyroid hormone (PTH) has been described in maintenance dialysis patients. The proposed etiology has centered upon the transfer of an environmental agent (aluminum) from the dialysis water system. The present report describes an azotemic patient, who, prior to the initiation of dialytic therapy, presented with severe osteomalacia and low PTH concentrations for the severity of renal failure. The osteomalacia was documented by bone histology on two occasions 1 year apart, and aluminum deposits at the osteoidmineralized bone interface were demonstrated with histologic techniques. PTH concentrations were within the normal range (less than 0.1 ng/ml) on three widely spaced intervals. No definite statement can be made regarding the etiology of the osteomalacic syndrome in this patient, but maintenance dialysis does not appear to be necessary for its expression.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7180912     DOI: 10.1159/000166631

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  9 in total

1.  A different interaction between parathyroid hormone, calcitriol and serum aluminum in chronic kidney disease; a pilot study.

Authors:  Fatih Mehmet Azik; Mesiha Ekim; Onur Sakallioglu; Ahmet Aydin
Journal:  Int Urol Nephrol       Date:  2010-06-10       Impact factor: 2.370

Review 2.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

3.  Histological and electron microprobe studies of mineralisation in aluminium-related osteomalacia.

Authors:  B F Boyce; J Byars; S McWilliams; M Z Mocan; H Y Elder; I T Boyle; B J Junor
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

4.  Aluminium osteomalacia in chronic renal failure patients neither on dialysis nor taking aluminium containing phosphate binders.

Authors:  A A O'Brien; D P Moore; J A Keogh
Journal:  Ir J Med Sci       Date:  1990-03       Impact factor: 1.568

Review 5.  Recent advances and controversies in childhood renal osteodystrophy.

Authors:  O Mehls; I B Salusky
Journal:  Pediatr Nephrol       Date:  1987-04       Impact factor: 3.714

Review 6.  Drug-induced rheumatic syndromes. Diagnosis, clinical features and management.

Authors:  M G Cohen; M V Prowse
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 May-Jun

7.  Interactions between aluminum and the actions and metabolism of vitamin D3 in the chick.

Authors:  H L Henry; A W Norman
Journal:  Calcif Tissue Int       Date:  1985-09       Impact factor: 4.333

Review 8.  Safety of new phosphate binders for chronic renal failure.

Authors:  Mahmoud Loghman-Adham
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Adynamic bone disease-bone and beyond.

Authors:  Vincent M Brandenburg; Jürgen Floege
Journal:  NDT Plus       Date:  2008-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.